

Behavioral, Cellular and Molecular Responses to Cold and Mechanical Stimuli in Rats with Bilateral Dopamine Depletion in the Mesencephalic Dopaminergic Neurons

Mennatallah Elshennawy, Omar Ouachikh, Youssef Aissouni, Shahira Youssef, Shahira Zaki, Franck Durif, Aziz Hafidi

▶ To cite this version:

Mennatallah Elshennawy, Omar Ouachikh, Youssef Aissouni, Shahira Youssef, Shahira Zaki, et al.. Behavioral, Cellular and Molecular Responses to Cold and Mechanical Stimuli in Rats with Bilateral Dopamine Depletion in the Mesencephalic Dopaminergic Neurons. Neuroscience Research, 2021, 479, pp.107. 10.1016/j.neuroscience.2021.10.026 . hal-04323726

HAL Id: hal-04323726 https://hal.science/hal-04323726v1

Submitted on 5 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Behavioral, cellular and molecular responses to cold and mechanical stimuli in rats with bilateral dopamine depletion in the mesencephalic dopaminergic neurons.

Mennatallah ELSHENNAWY 1,2, Omar OUACHIKH 2, Youssef AISSOUNI 3, Shahira YOUSSEF 1, Shahira S. ZAKI 1, Franck DURIF 2 and Aziz HAFIDI 2

Affiliations:

1: Anatomy and Embryology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt

2 : Université Clermont Auvergne, CHU, CNRS, Clermont Auvergne INP, Institut Pascal, 63000 Clermont-Ferrand, France.

3 : Université Clermont Auvergne, INSERM, NeuroDol U1107, 63000 Clermont-Ferrand, France.

Corresponding author: aziz.hafidi@uca.fr

Keywords: Parkinson disease, allodynia, hyperalgesia, cold, mechanical

Statistics: Title: 166 characters including spaces; Summary: 259 words, Text: 6856 words, 11 Figures, 3 Tables, 113 References.

Running Title: Cold impairment in mesencephalic dopamine depleted rats

Acknowledgment: The Missions Sector of the Ministry of Higher Education and Scientific Research in Egypt; Ain Shams University, Egypt and Clermont Auvergne University, France funded this study, and all authors declare that there is no conflict of interest.

Author contributions:

All authors contributed substantially to this study: conception and design of the study (M.E, O.O., A.H); acquisition and interpretation of data (M.E., O.O, A.H., Y.A); drafting of the article (F.D., S.Y., S.S.Z), intellectual revision of the article (M.E., O.O., A.H); and approval of the last version of the manuscript (M.E., O.O., A.H., F.D., S.S.Z., S.Y., Y.A).

Declarations of interest: None

Funding: The Missions Sector of the Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt; Ain Shams University, Egypt and Clermont Auvergne University, France funded this study, and all authors declare that there is no conflict of interest.

E-mail addresses for all authors: menna.faisal@med.asu.edu.eg; omar.ouachikh@uca.fr; youssef.aissouni@inserm.fr; shahira_youssef@med.asu.edu.eg; shahira_samir@med.asu.edu.eg; franck.durif@uca.fr; aziz.hafidi@uca.fr

Abstract

Pain is the major non-motor symptom in Parkinson's disease (PD). Preclinical studies have mostly investigated mechanical pain by considering the decrease in a nociceptive threshold. Only a few studies have focused on thermal pain in animal models of PD. Therefore, the goal of this study was to assess the thermal nociceptive behavior of rats subjected to 6hydroxydopamine (6-OHDA) administration, which constitutes an animal model of PD. Thermal plate investigation demonstrated significant thermal sensitivity to cold temperatures of 10 °C and 15 °C, and not to higher temperatures, in 6-OHDA-lesioned rats when compared with sham. 6-OHDA-lesioned rats also showed cold allodynia as demonstrated by a significant difference in the number of flinches, latency and reaction time to acetone stimulus. Ropinirole administration, a dopamine receptor 2 (D2R) agonist, blocked the acetone-induced cold allodynia in 6-OHDA-lesioned rats. In addition, mechanical hypersensitivity and static allodynia, as demonstrated by a significant difference in the vocalization threshold and pain score respectively, were noticed in 6-OHDA-lesioned rats. Acetone stimulus induced a significant increase in extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) phosphorylation, a pain process molecular marker, in the spinal dorsal horn (SDH), the insular and cingulate cortices in 6-OHDA-lesioned rats when compared to sham. In 6-OHDAlesioned rats, there was a significant augmentation in the expression of both protein kinase C gamma (PKCy) and glutamate decarboxylase 67 (GAD67) in the SDH. This highlighted an increase in excitation and a decrease in inhibition in the SDH. Overall, the present study demonstrated a clear cold thermal hypersensitivity, in addition to a mechanical one, in 6-OHDA-lesioned rats.

Introduction

Parkinson's disease (PD), which is the second most prevalent neurodegenerative disorder, results from the death of dopamine-containing cells in the substantia nigra pars compacta (SNc). The disease is characterized by motor symptoms, such as resting tremor, rigidity, akinesia and postural instability, and non-motor symptoms. The latter are often reported by patients before the diagnosis of PD (Skogar and Lokk, 2016; Tseng and Lin, 2017; Jankovic and Tan, 2020). Pain represents the main non-motor symptom of PD and epidemiological studies have estimated its prevalence between 68 % and 95 % (Buhmann et al., 2020). All of the symptoms generally occurred in the off-period of the treatment (Barcelo et al., 2010; Fil et al., 2013; Blanchet and Brefel-Courbon, 2018) and disappeared after levodopa treatment (Young Blood et al., 2016). A decrease in chemical, mechanical and thermal thresholds have been stated in both PD patients and animal models (Takeda et al., 2005; Chudler and Lu, 2008; Marques et al., 2013; Zenkin-Toktas et al., 2013; Dieb et al., 2015; 2016 a-b; Buhidma et al., 2020). After electrical stimulation, electromyogram recording showed that the heat pain threshold had decreased and the spinal nociceptive threshold had changed in PD patients (Mylius et al., 2015). The mechanism of although, in different studies, (Wood, 2006; pain is not yet well understood in PD patients, Chudler and Lu 2008; Borsook, 2012; Young Blood et al., 2016), it was noted that the basal ganglia were involved in pain pathogenesis. For example, neuropathic pain (NP) was exaggerated due to the loss of dopamine (DA) in the striatum (Takeda et al., 2005; Taylor et al., 2014). On the other hand, the pain was diminished when amphetamine was infused into the nucleus accumbens (Altier and Stewart, 1999; Harris and Peng, 2020). The administration of the dopamine receptor 2 (D2R) agonist to the striatum reduced the sensation of pain (Magnusson and Fisher, 2000; Wawrzczak-Bargieła A, 2020).

Spontaneous and evoked pains clinically characterize NP. It can occur as a dysfunction in the peripheral or the central nervous systems (Viana, 2018). NP can be characterized by allodynia or hyperalgesia (Sandkühler, 2009; Jensen and Finnerup, 2014). Only a few studies, in which the 6-hydroxydopamine (6-OHDA) rat constituted the PD model, have explored pain in bilateral denervation (Paillé et al., 2007) of the nigrostriatal pathway (Zenkin-Toktas et al., 2013; Dieb et al., 2014; 2016 a-b). Therefore, the present study explored mechanical and thermal hyperalgesia and cold allodynia (reduced pain threshold) in the hind paw of a rat model of PD with a bilateral 6-OHDA lesion of the medial forebrain bundle (MFB). In addition, the effect of ropinirole, a D2R agonist, was investigated pharmacologically in mechanical hyperalgesia and thermal cold allodynia. Many of the NP symptoms, such as allodynia, are a result of changes within the spinal dorsal horn (SDH) (Sandkühler, 2009). Therefore, two markers were used to investigate segmental sensitization at both the cellular and molecular levels. Protein Kinase C © (PKC©), which labels cells within the SDH lamina II and plays an important function in pain chronicity (Dieb et al., 2015; Todd, 2017); and the phosphorylation of extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), which is expressed under noxious stimuli in the SDH (Ji et al., 1999; Polgár, 2007). Active ERK1/2 (pERK1/2) represents a molecular marker for pain processes (Ji et al., 1999; Liu et al., 2012; Dieb and Hafidi, 2015). In addition, the insular and anterior cingulate cortices are involved in the neuropathic pain process (Ohara et al., 2005) and both structures receive dopaminergic projections from the SNc (Chudler and Dong, 1995; Zhang et al., 2017). Their involvement in the pain process, in the rat model of PD, has been explored by observing pERK1/2 expression.

MATERIALS AND METHODS

Animals

Experiments were performed using 65 adult male Sprague-Dawley rats (Charles River, France) initially weighing 280–350 g. The Rats were housed three per cage in a Specific Pathogen Free facility under standard laboratory conditions (12/12 light/dark cycle, light on at 8:00 am) and were allowed free access to food pellets and water. The Rats were acclimatized for one week after transport to the animal house. 6-OHDA-lesioned rats included in the experiments were the rats showing signs of motor impairment (hind limb rigidity), aphagia, and/ or adipsia. Rats with signs of deterioration, for example, having lost more than 20 % of their bodyweight over the 6 days after surgery, were euthanized and excluded from the experiments. The experiments complied with the ethical guidelines of the animal ethics committee of Clermont Auvergne University (APAFIS#19965-20190325052285).

Surgery

6-OHDA lesion:

The Rats were anesthetized with Ketamine 60 mg/kg and xylazine 10 mg/kg, intraperitoneal (i.p) and were positioned on a stereotaxic frame (David Kopf Instrument, CA, USA) to undergo a bilateral injection of 6-OHDA into the MFB [concentration of 3 μ g/ μ L] with the rate (0.25 μ L/min) in two deposits (2.25 and 2.85 μ l). The 6-OHDA was dissolved in a vehicle solution (0.02% ascorbate saline) (Sigma-Aldrich, France, # H4381). The Injections were done at the following coordinates (Table 1) under aseptic conditions (Dieb et al., 2016): **Table 1.** Coordinates of the 6-OHDA lesion surgery:

Deposit	Anterior	Lateral	Ventral	Tooth bar
2.25 µl,	-4.0	± 0.8	-8.0	+3.4
2.85 µl,	-4.4	± 1.2	-7.8	-2.4

To protect the adrenergic neurons from 6-OHDA toxicity, the animals were injected with desipramine (25 mg/kg, i.p., Sigma-Aldrich, Saint-Quentin-Fallavier, France, # D3900) 30 minutes before the 6-OHDA injection. Desipramine was used in our animal model to focus on dopaminergic depletion in pain and to limit the noradrenergic effect. Sham-lesioned rats were only injected with the vehicle at the same coordinates. The injection syringe was retracted

slowly 1 mm/minute. The physical appearance of the rats and their body temperature were monitored regularly, as were the surgical sutures to ensure they remained in place and that the head incision was well coated. 6-OHDA-lesioned rats were fed with wet food pellets, milk, and water until they were able to feed themselves.

Study Design

From our previous studies, we know that the 6-OHDA-lesioned rat had pain hypersensitivity for up to three months (Dieb et al., 2016 b). To decrease the number of rats used, experiments were organized to test the same animals within a certain timeframe and add some when it was needed. Also, experiments were done over time to make sure that the animals had no effects from previous experiments. The D2R agonist was investigated in all tests when it could be done easily without harming the rats (intrathecal administration and von Frey filament test, intraperitoneal injection, and acetone test). Due to the half-life of ropinirole [30 minutes in rats, (Ramji et al., 1999)], we were not able to do the paw pressure test. In addition, since the thermal place preference test showed hypersensitivity to cold temperatures, the D2R was tested in the acetone drop.

The thermal place preference test

The thermal place preference (TPP) test was used (Balayssac et al., 2014) one week after surgery. The apparatus consisted of two hot/cold plates (165X165 mm; Bioseb, Chaville, France). Every plate was regulated at ± 0.1 °C. The reference plate was set at 25 °C, while the test plate at (10 °C to 50 °C) according to the required temperature. For each session (3 minutes), the rat was positioned in the middle of the apparatus and was permitted free movement between the two plates. The time the rat passed on each test plate was calculated as a percentage. To avoid any possibility of habituation, the reference and test plates were permuted between each session. The animals were acclimatized to the experimental conditions, using two plates set at 25 °C, before the test.

Mechanical hyperalgesia

Hypersensitivity to mechanical stimuli was conducted by applying a gradually increasing pressure stimulus using the Ugo Basile analgesiometer (Randall-Selitto apparatus, Bioseb, France), (Randall and Selitto, 1957), at two and four weeks after surgery. The rats left and right hind paws were subjected to an incremental linear mechanical force (measured in grams)

until a squeak was observed marking a painful threshold. To habituate the rats, the experimenter handled them for 20 seconds two or three times beginning, three days before the experiment. This was also repeated on the day of the experiment before putting the rats on the Ugo Basile apparatus. An increasing pressure was then exerted by applying the tip of the apparatus on the paw until the rat's vocalization was obtained. It was easier and more reliable to monitor vocalization than motor response. The vocalization threshold was measured three times to obtain two consecutive values that differed < 10 %, with a minimum of 10 minutes between each measurement and the following one. The pressure threshold of vocalization was obtained at a cut-off value of 250 g.

Von Frey filament test

The rats were subjected to mechanical stimulation with a von Frey filament to test allodynia in the hind paw (Chaplan et al., 1994) at two and four weeks after surgery. Each rat was acclimatized for 1 hour on a metal mesh floor, under a small plastic cage (35x20x15 cm). Tactile allodynia was set with the use of non-noxious 10 g von Frey filament (Bioseb, Chaville, France) (Chaplan et al., 1994). Painful behavior was noted when there was paw withdrawal and/or an escape trial. All experiments were done relatively at the same time of the day. Ropinirole was injected intrathecally two weeks after surgery into a 6-OHDA-lesioned group and the pain score was calculated relative to another 6-OHDA-lesioned group, which had the saline intrathecal injection.

Intrathecal injection

Intrathecal injection of ropinirole was done according to the method described by Mestre et al., 1994. Briefly, the rats were tightly restrained. Ropinirole (20 nmol) (Tang et al., 2021) or 10 μ L of saline solution using a 30-gauge needle was injected intrathecally (i.t.) in between L4 and L5 of the spinal cord. The success of the procedure was confirmed by tail-flick on injection of ropinirole as indicated by Mestre et al., 2009. Pain score (paw withdrawal) was evaluated pre-injection and every 6 minutes up to 36 minutes after ropinirole injection. Spinal cord L3-L4 constitute the segments regulating the sensory process at the level of posterior paws (Takahashi et al., 1994). In addition, acetone drop and von Frey filaments were tested in the posterior paw. For these reasons, ropinirole was administered at the level of L3-L4.

Acetone drop test

The acetone test (Choi et al., 1994) was performed at ten days after surgery for four days successively to test cold hyperalgesia-like (cold allodynia) reactions in the hind paws of three animal groups: sham, 6-OHDA-lesioned and 6-OHDA-lesioned rats with acute intraperitoneal administration (for 4 days, starting at day 10 post-surgery) of ropinirole-hydrochloride (D2R agonist, 5 mg/Kg/ml, Sigma-Aldrich, Saint-Quentin-Fallavier, France, # R2530) (Mavrikaki et al., 2014, Tremblay et al., 2017). The ropinirole treated group is referred to as the 6-OHDA +D2R agonist group, a behavioral test was done after 15 minutes post-injection (Mavrikaki et al., 2014) for this group. The Rats were acclimatized for 15 minutes on a metal mesh floor, under small plastic cages (35x20x15 cm). An acetone drop from a 1 m syringe was gently applied to the hind paw plantar surface (without touch). Three parameters were tested using the acetone stimulus. Each parameter was considered after the application of acetone 5 times (with a 5 minute interval between successive applications). The first one was the number of flinches, for which the number of hind paw withdrawals was counted for five consecutive applications. The second parameter was the latency, for which the duration between the application of acetone and the hind paw reaction was measured. While the third parameter was the reaction time which was assessed for the duration of two minutes. The test was repeated for four successive days in the second week after surgery and the median + interquartile range values were calculated.

The behavioral experiments were done with a blind design so that the experimenter could not recognize the different animal groups.

Immunohistochemistry

At the end of the behavioral experiments, ketamine (60 mg/kg) and xylazine (10 mg/kg) i.p. were used to deeply anesthetise the rats which were perfused transcardially with a warm (37 °C) heparinized saline solution (25 IU heparin/ml) followed by a cold (10 °C) phosphate-buffered solution (0.1 M, pH 7.6) containing 4% paraformaldehyde and 0.03% picric acid for 15 minutes. Brains and spinal cords were then removed and placed in a solution of 30% sucrose and 0.05% sodium azide at 4 °C overnight. Coronal sections (40 μ m) were collected with a using a freezing microtome and placed in a 0.05 M Tris-buffered saline (TBS) solution. Free-floating sections were placed in 1% normal goat serum at room temperature for 1 hour before overnight incubation in primary mouse monoclonal anti-TH antibody solution (1:5000, Sigma-Aldrich, Saint-Quentin-Fallavier, France, #T2928), rabbit monoclonal anti-

pERK1/2 (1:200, Cell Signaling Technology, Ozyme Saint-Cyr-l'École, France, #4370), rabbit monoclonal anti-GAD1 (1:1000, Cell Signaling Technology, #41318) and mouse monoclonal anti-PKC© (1:500, Santa- Cruz Biotechnology, France, #sc-166385). After several rinses, sections were incubated with a secondary antibody (1:500 for goat anti-mouse 488 #4408; goat anti-rabbit 555 #4413, goat anti-mouse 555 #4409, goat anti-rabbit 488 #4412, Cell Signaling Technology) for 2 hours at room temperature. All the antibodies were diluted in TBS containing 0.25 % bovine serum albumin and 0.3 % TritonX-100. The sections were finally rinsed in TBS, mounted onto Thermo Scientific Superfrost Plus slides (Fisher Scientific, UK), and coverslipped with Dako Fluorescence Mounting Medium (Agilent, United States). The specificity of immunostaining was assessed by omitting the primary antibody, which resulted in the absence of the signal. Photomicrographs of immuno-stained sections were captured using a motorized Zeiss Axioplan 2 microscope equipped with a Hamamatsu C4742-95 digital camera (Hamamatsu Photonics France SARL, Massy, France) (switching between FITC and Texas Red filter sets) driven by MetaMorph 5.4 software. In each rat, image acquisition was done using multiple sections depending on the structure taken (Table 2). The Measurement of PKCy positive cell number was taken from the whole lamina IIi of SDH, as it contains the majority of the PKCγ positive neurons (Dieb et al., 2016 a-b), using sections that were taken from the Lumbar (L3 - L6) spinal cord region. The final data were presented as a median + interquartile range value of the total sections of each group. The pERK1/2-positive cells were counted in all of the superficial laminae in the multiple sections at the level of the Lumbar (L3 - L6) spinal cord region. While for the insular and cingulate cortices, rostro-caudal slices from (2.04 mm to - 0.48 mm relative to Bregma) were taken, a square area of equal dimensions was applied to all counted sections. Tyrosine hydroxylase (TH) immunolabeling was quantified in the whole sections, at different slices, at the level of SNc and ventral tegmental area (VTA). Rostro-caudal sections from (-5.16mm to -6.12mm) were analyzed.

The cells for all PKC γ , pERK1/2, and TH were quantified using the multipoint cursor of ImageJ Software (ImageJ v1.6, National Institutes of Health, Bethesda, MD) where the numbers of cells were displayed in the results window. Cell count was done with a blind observer who did not know the different animal groups.

Cell Count Measurement					
Antibody	Structure	Group	Number of sections		
PKC©	Spinal cord	Sham	18		
		6-OHDA-lesioned	25		
		6-OHDA +D2R agonist	33		
pERK1/2	Spinal cord	Sham	28		
		6-OHDA-lesioned	32		
		6-OHDA +D2R agonist	38		
	Insular cortex	Sham	9		
		6-OHDA-lesioned	10		
		6-OHDA +D2R agonist	18		
	Cingulate cortex	Sham	10		
		6-OHDA-lesioned	16		
		6-OHDA +D2R agonist	24		
ТН	SNc and VTA	Sham	27		
		6-OHDA-lesioned	13		

Table 2. The number of sections of each group used for each antibody:

GAD67 and PKC γ fluorescence intensities were compared throughout different spinal cord sections at the level of the Lumbar (L3 – L6) region.

Western Blot

At the end of behavioral experiments, sham, 6-OHDA-lesioned and 6-OHDA +D2R agonist groups were anesthetized with ketamine (60 mg/kg) and xylazine (10 mg/kg) and sacrificed by decapitation. Fresh spinal cord tissues (spinal cord from L3 to the end of the spinal cord) and fresh pieces from insular and cingulate cortices bilaterally (2mm) were punched, snap-frozen in liquid nitrogen, and stored at -80 °C until use. Each sample was homogenized with a glass homogenizer in 200 µl of lysis buffer (50 mM HEPES, pH 7.5, 1 % TritonX-100, 10mM EDTA, 150mM NaCl, 10mM Na4P2O7, 0.1M NaF, 2mM vanadate) supplemented with PMSF 0.5 mM, completeTM, Protease Inhibitor Cocktail (Sigma Aldrich, #5892970001) and Triton 1%, sonicated for 3 minutes and incubated on ice for 20 minutes. 100-µl of extraction

buffer was added to each sample before centrifugation at 14,000 g for 15 minutes at 4 °C. The supernatants were collected in clean tubes and stored at -80 °C until use. The total amount of protein in each sample was measured using the BCA Protein Assay Kit (Pierce-Thermo Scientific, Illkirch-Graffenstaden, France) before loading on polyacrylamide gels. Samples (40 µg) were separated using 4-20 % Mini-PROTEAN TGX polyacrylamide gels (BioRad, Roanne, France) and transferred to nitrocellulose membranes using the Wet/Tank Blotting System (BioRad). After the blots had been washed with TBS-T (10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.01% Tween-20), they were blocked with 5% BSA in TBS-T for 1 hour at room temperature. Then the membranes were incubated at 4 °C overnight with primary antibodies diluted in 5% BSA in TBS-T. The Primary antibodies used were rabbit monoclonal anti-pERK1/2 (1:500, Cell Signaling Technology, #4370), rabbit monoclonal anti-GAD1 (1:1000, Cell Signaling Technology, #41318), mouse monoclonal anti-PKCy (1: 400, Santa-Cruz Biotechnology, France, #sc-166385) and rabbit polyclonal anti-GAPDH (0.2 µg/ml, Sigma-Aldrich, #G9545). After washing with TBS-T, membranes were incubated for 1 hour with HRP-conjugated anti-rabbit and anti-mouse IgG secondary antibodies (1:5000, Invitrogen-Thermo Scientific #31460, #31430, respectively) diluted in 5% BSA in TBS-T. The bands were visualized with Clarity[™] western ECL substrate solution (Bio-Rad, USA) and the positive pixel areas of specific bands were measured with a computer-assisted image analysis system (ChemiDoc XRS, Bio-Rad, USA) and normalized against the corresponding GAPDH loading control bands. The 6-OHDA-lesioned group and the 6-OHDA +D2R agonist one were normalized against the sham group of the corresponding gel to be able to compare the different gels. Results are expressed as the median \pm interquartile range of expression levels of the ratio between 6-OHDA-lesioned and 6-OHDA +D2R agonist to the sham group of each gel.

Body weight analysis

Because bilateral lesions of the MFB may cause aphagia and/or adipsia, the animals' weight was checked daily after surgery. 6-OHDA-lesioned rats were not able to self-feed. They were fed (wet food pellets + milk + water) by syringe feeding twice a day, for 8 to 10 days.

Statistical analysis

The results are expressed as median \pm interquartile range. Statistical analysis was performed using one-way ANOVA to compare the three groups, followed by Tukey's posthoc multiple comparisons test for parametric data and the Kruskal-Wallis test, followed by Dunn's posthoc multiple comparisons test for non-parametric data. Normality tests were done using the Shapiro-Wilk normality test, if parametric, Levene's test was done to check for equal variances (supplementary material). Two-way ANOVA, followed by Sidak's posthoc multiple comparisons test and Friedman's test were used when convenient. In addition, Student's Ttest was used when the comparison between only two groups was required for parametric data and the Mann-Whitney test for non-parametric data. The level of significance was determined at a P-value ≤ 0.05 . Data were analyzed using GraphPad Prism Software (v.8.0.2) and SPSS (v. 1.0.0.1447). Fixed-effect model ANOVA was used as variables were fixed factors in the experiment. Also, in the two-way ANOVA analysis, variables were fixed factors in both rows and columns factors.

Results

Thermal hyperalgesia (Figure 1)

Thermal sensitivity was tested one week after surgery; the rats were tested for thermal place preference (Fig.1) at different temperature degrees (10 °C, 15 °C, 25 °C, 35 °C, and 50 °C). The 6-OHDA-lesioned rats showed a significantly higher thermal sensitivity when compared with the sham ones. This increase was observed with the temperatures 10 °C and 15 °C, as the 6-OHDA-lesioned rats spent less time on the test plate than sham ones. While at 50 °C, the sham rats spent less time than 6-OHDA-lesioned rats on the plate. For the other temperatures, 25 °C and 35 °C; there was no significant difference observed between the groups.

Cold allodynia (Acetone test, Figure 2)

Cold allodynia was tested during the second week in the three groups; sham, 6-OHDAlesioned, and 6-OHDA +D2R agonist. 6-OHDA-lesioned rats had a significant increase in cold allodynic behavior, which was shown by an increasing number of flinches, the reaction time and latency in comparison with the sham group. Ropinirole had a significant role in decreasing allodynic behavior, which was evident from the significant decreases of reaction time and latency between the 6-OHDA +D2R agonist group and the 6-OHDA lesioned one.

Mechanical hyperalgesia and static allodynia (Figure 3)

Mechanical hyperalgesia and mechanical static allodynia were tested at two and four weeks after surgery using the Randall-test (Fig. 3A) and non-noxious 10 g von Frey filament (Fig. 3B), respectively. The 6-OHDA-lesioned rats had greater mechanical hyperalgesia and mechanical static allodynia than the sham group, as was substantiated by the increase in vocalization at 50 % of the baseline score and the increase in paw withdrawals at two and four weeks after surgery, respectively.

pERK1/2 expression in the spinal dorsal horn (Figure 4)

pERK1/2 labeling expression upon paw acetone stimulus was observed in the superficial laminae of the SDH in the sham (Fig. 4A), 6-OHDA-lesioned (Fig. 4B), and 6-OHDA +D2R agonist rats (Fig. 4C). pERK1/2-positive cells were quantified in the SDH superficial laminae in the three animal groups. The 6-OHDA-lesioned rats had a significant increase in pERK1/2 in comparison with both the sham and 6-OHDA +D2R agonist groups. Ropinirole intraperitoneal administration led to a significant decrease in pERK1/2 in the 6-OHDA +D2R

agonist rats when compared with the 6-OHDA-lesioned ones, while the sham group showed a less significant decrease. Western blot (Fig. 4E) revealed a significant pERK1/2 protein difference between the 6-OHDA-lesioned rats and both the sham and 6-OHDA +D2R agonist rats (Fig. 4F).

PKCγ expression in the spinal dorsal horn (Figure 5)

PKC γ labeling is localized in the SDH superficial laminae cells in the sham (Fig. 5A), 6-OHDA-lesioned (Fig. 5B), and 6-OHDA +D2R agonist rats (Fig. 5C). PKC γ labeling was quantified using the number of positive cells (Fig. 5D). The 6-OHDA-lesioned rats had more PKC γ expression than both the sham and 6-OHDA +D2R agonist groups regarding the number of cells. Also, the 6-OHDA-lesioned rats had more intense fluorescent labeling than both the sham and 6-OHDA +D2R agonist rats. Ropinirole intraperitoneal administration led to a significant decrease in PKC γ expression in the 6-OHDA +D2R agonist rats when compared with the 6-OHDA-lesioned ones regarding the fluorescence intensity and the number of cells. While there was a non-significant increase in western blot band intensities between the 6-OHDA-lesioned and both the sham and 6-OHDA +D2R agonist groups.

GAD67 expression in the spinal dorsal horn (Figure 6)

GAD67 labeling was expressed throughout the SDH laminae in the sham (Fig. 6A), 6-OHDAlesioned (Fig. 6B), and 6-OHDA +D2R agonist animals (Fig. 6C). The 6-OHDA-lesioned groups demonstrated more of an augmentation in the GAD67 expression more than either of the sham or 6-OHDA +D2R agonist groups did, as shown by the increase in fluorescence intensity of the 6-OHDA-lesioned group over the other two groups. In addition, there was an increase in the western blot band intensity of the 6-OHDA lesioned group in comparison with the sham and 6-OHDA +D2R agonist animals. Ropinirole intraperitoneal administration led to a significant decrease in GAD67 expression in the 6-OHDA +D2R agonist rats in relation to the 6-OHDA-lesioned ones.

pERK1/2 expression in the Insular and the Cingulate cortices (Figures 7-8)

In the insular cortex, pERK1/2 labeling was expressed in the cell bodies and dendrites of somata located across the different cortical layers in the sham (Fig. 7A), 6-OHDA-lesioned (Fig. 7B), and 6-OHDA+D2R agonist (Fig. 7C) groups. These cells had mostly pyramidal cell morphology. The 6-OHDA-lesioned group showed an increase in pERK1/2 as revealed by its quantification and the increase in western blot band intensity when compared with both the

sham and the 6-OHDA +D2R agonist rats. Ropinirole intraperitoneal administration led to a significant decrease in pERK1/2, as was substantiated by the diminution in pERK1/2 expression in the 6-OHDA +D2R agonist rats more than in the 6-OHDA lesioned ones, when taking into account the number of cells and band intensity.

In the cingulate cortex, pERK1/2 labeling was observed in the cell bodies and dendrites of the cells located mostly within the deep layers in the sham (Fig. 8A), 6-OHDA-lesioned (Fig. 8B), and 6-OHDA +D2R agonist groups. (Fig. 8C). The 6-OHDA-lesioned group showed a significant increase in pERK1/2, as was revealed by the increase in pERK1/2 quantification when compared with both the sham and 6-OHDA +D2R agonist rats, in addition to its increase in western blot band intensity in the 6-OHDA-lesioned group compared with the sham rats. Ropinirole intraperitoneal administration led to a significant decrease in pERK1/2 expression in the 6-OHDA +D2R agonist rats more than in the 6-OHDA-lesioned ones, when taking into account the number of cells and band intensity.

Intrathecal ropinirole administration (Figure 9)

To test segmental involvement in the pain process, ropinirole was intrathecally administered and the rats were then subjected to a non-noxious 10 g von Frey filament test. Intrathecal administration of ropinirole led to a decreasing pain score (paw withdrawal) in the 6-OHDA-lesioned rats in comparison with saline-injected, 6-OHDA-lesioned rats. The pain score decrease remained evident for up to 25 minutes.

TH immunostaining in the 6-OHDA-lesioned rats (Figure 10)

TH labeling was explored in the SNc and ventral tegmental area (VTA) in both the sham (Fig. 10A) and 6-OHDA-lesioned groups (Fig. 10B) in order to highlight the effects of 6-OHDA toxin in the MFB lesion. TH labeling was observed in the somata and processes in the SNc and VTA. A general extreme significant decrease in the TH staining was observed in the 6-OHDA-lesioned rats when compared to sham confirming the degeneration of dopaminergic cells. The Quantification of TH cells in SNc and VTA (Fig. 10C) demonstrated a 67.8 % decrease in cell number between the 6-OHDA-lesioned and sham groups. A significant 56.7 % decrease in TH positive cell number was also observed between the 6-OHDA-lesioned and sham rats in the VTA (Fig. 10D). As well, a significant 89.9 % decrease was obtained in TH positive cell number between the 6-OHDA-lesioned and sham groups in the SNc (Fig. 10E).

Body weight

After surgery, the 6-OHDA-lesioned group had a significantly decreased body weight due to aphagia and adipsia. A considerable weight difference was observed in the 6-OHDA-lesioned rats in comparison with the sham ones (Fig. 10F).

Discussion

The main results of this study showed that bilateral 6-OHDA-lesioned rats demonstrated an increase in thermal sensitivity to cold temperatures. This sensitivity was supported by the presence of cold allodynia, which was exhibited by the acetone test. In addition, lesioned rats demonstrated the presence of both mechanical hyperalgesia and mechanical static allodynia. Acetone stimulation promoted the expression of pERK1/2 in the SDH, the insular, and cingulate cortices, thus implicating these structures in the pain-process in both 6-OHDA-lesioned rats was considerably elevated when compared with the sham ones. In addition, the 6-OHDA lesion induced an increase in the expression of PKC γ and GAD67 (glutamate decarboxylase) in the SDH. These two proteins may highlight an increase in excitation (PKC γ) and a decrease in inhibition (GABA), respectively. Moreover, the use of ropinirole, a D2R agonist, reversed the expression of PKC γ and GAD67 in the SDH and alleviated the pain sensitivity. These results demonstrated a clear implication of the SDH and dopamine in the pain process in 6-OHDA-lesioned rats.

Although a study has shown that ketamine had a neuroprotective role in the 6-OHDA PD model (Ferro et al., 2007), according to our previous work, (Ouachikh et al., 2013; Ouachikh et al., 2014; Dieb et al., 2014; Dieb et al., 2016a-b), there was always a neuronal cell death percentage over 60% while using ketamine. This allowed us to consider that we are in an animal model of PD. Therefore, the use of ketamine as an anesthetic did not constitute an obstacle to neuronal degeneration.

Pain is measured through the motor and non-motor reflexes. Different studies using 6-OHDA-lesioned animals showed a reduction in mechanical and thermal nociceptive thresholds or allodynia in both hind paws without the affection of their motor functions (Saadé et al., 1997; Takeda et al., 2005; Paillé et al., 2007; Dieb et al., 2015; 2016 a-b; Campos et al., 2019; Tang et al., 2021). In addition, 6-OHDA lesions generally showed a contralateral motor deficit along with bilateral pain (Chudler and Lu, 2008; Dieb et al., 2015; 2016 a-b). After the lesion, while there was motor improvement, pain scores remained similar over time. This showed the probable occurrence of compensatory modulation in motor circuits, which did not apply to the pain pathway. In PD patients, pain occurrs before the onset of motor symptoms (O'Sullivan et al., 2008; Tseng and Lin, 2017), and increases with disease progression (Stamey et al., 2008; Barone et al., 2009). Together, these data infer that in the 6-

OHDA-lesioned animal, pain may be associated with dopamine depletion rather than motor deficit.

The 6-OHDA-lesioned rats developed sensitivity to cold temperature (TPP test) and cold allodynia (acetone test). In addition, these rats also developed mechanical hyperalgesia and allodynia. Noxious cold stimuli activate nociceptive C and Aδ afferents, some of which are of a polymodal subtype and respond to a mechanical stimulus (Simone and Kajander, 1996; Dubin and Patapoutian 2010; Sneddon, 2018). These afferent subtypes are probably under central dopaminergic regulation and may be involved in both the mechanical and cold sensitizations observed in 6-OHDA-lesioned rats. SNc probably modulates pain through the inhibition of nociceptive inputs at the spinal cord neuron level (Pasquier et al., 1977; Barnes et al., 1979; Beckstead et al., 1979; Von Krosigk and Smith, 1991) or ascending projections to cortical areas such as insular and / or cingulate cortices (Beckstead et al., 1979; Burkey et al., 1999; Ohara et al., 2003). This is highlighted here by the expression of pERK1/2 at the level of the SDH and the insular and cingulate cortices. pERK1/2 was expressed under noxious and not non-noxious stimuli (Ji et al., 1999; Dieb et al., 2015; 2016 a-b). pERK1/2 was highly expressed in these structures in the 6-OHDA-lesioned rats and the administration of D2R agonist ropinirole decreased its expression. This result agrees with previous studies showing an elevation of pERK1/2 expression and its decrease using bromocriptine, another D2R agonist in 6-OHDA-lesioned rats (Dieb et al., 2016 a-b). Although the intraperitoneal administration of ropinirole may have affected a variety of brain structures, here, it is demonstrated to affect pain processing structures such as insular and cingulate cortices, in addition to SDH. The latter is clearly involved in the pain process as demonstrated by the changes in the different markers at this level. In addition, the effect of intrathecal ropinirole administration on pain (von Frey test) is in support of the segmental involvement of the pain process in 6-OHDA-lesioned rats.

Most of the data in animals (Domenici et al., 2019; Tang et al., 2021) and humans (Brefel-Courbon et al., 2005) showed that dopamine or dopamine agonists did not affect pain in the control or sham animals. For this reason, and to decrease the number of animals needing to be used, a dopamine agonist was not tested on the sham animals.

The use of specific inhibitors of ERK phosphorylation demonstrated that ERK played a role in allodynia and hyperalgesia caused by spinal cord injury or chronic inflammatory and neuropathic pain (Cruz and Cruz, 2007). Since the question here was the phosphorylation of

pre-existing ERK and not the expression of ERK, the total ERK (phosphorylated and nonphosphorylated) was not taken into consideration. In addition, if the total ERK/pERK had been taken into consideration a difference might not have been obtained between the groups. Also, the time between stimulus and sacrifice of the animal was too short for protein synthesis. ERK phosphorylation is induced because of glutamate release (English and Sweatt 1996; 1997), and its binding to both NMDA and metabotropic receptors. It is also induced by neurotrophins through their binding to their tyrosine kinase receptors and by neurotransmitters, such as NPY. Phosphorylation of ERK modulates glutamate receptor and potassium channel activities (Adams et al., 2000; Hu et al., 2006) leading to increased neuronal excitability (Hu and Gereau, 2003). ERK phosphorylation contributes to LTP (Jones et al., 1999; Martin et al., 2000; Schafe et al., 2000; Wei et al., 2006) probably through the expression of different NMDA subunits. Phosphorylation of ERK mediates the windup phenomenon, which is a kind of central sensitization evoked during repetitive C-fiber stimulation (Fukui et al., 2007). More recent studies have also demonstrated a decrease in the mechanical and thermal thresholds in 6-OHDA-lesioned rats, thus implying a segmental pain process (Dieb et al., 2016; Charles et al., 2018; Campos et al., 2019). Moreover, the windup was higher in the 6-OHDA-lesioned when compared to the sham rats (Charles et al., 2018). The windup is modified by an endogenous opioid mechanism at the level of the SDH (Guan et al., 2006). This opioidergic system has been involved in the mechanical allodynia observed in the 6-OHDA model of PD (Campos et al., 2019). Together, these data imply a segmental pain process in PD animal models.

The present study also demonstrated an increase in the expression of PKC γ , a protein that is involved in pain chronicity (Malmberg et al., 1997; Dieb and Hafidi, 2015; Dieb et al., 2016 a-b). Inhibiting PKC γ also depressed the expression of pERK1/2 in the superficial laminae of the medullary dorsal horn and alleviated the pain in the rats (Dieb and Hafidi, 2015). pERK1/2 positive cells receive PKC γ ending innervations (Dieb and Hafidi, 2015). In the present study, ropinirole administration decreased both PKC γ and pERK1/2 expressions. Therefore, dopamine depletion in 6-OHDA-lesioned rats produced sensitization (increase in excitation) at the spinal dorsal horn level (Charles et al., 2018) increasing PKC γ cells excitation (increase in PKC γ staining) leading to the activation of pERK1/2 cells. The latter transfer non-painful stimuli to the pain processing pathway (Dieb and Hafidi, 2015). It is to be noted that, in our case, we have never found pERK1/2 or PKC γ in glial cells. A previous report of double immunostaining using NeuN antibody and pERK1/2 showed that they both colocalize in the same neurons (Dieb et al., 2015).

The administration of the D2R agonist, bromocriptine, lowered the expression of PKC γ , decreased the expression of pERK1/2 in the superficial laminae of the medullary dorsal horn, and alleviated the pain in 6-OHDA-lesioned rats (Dieb et al., 2016 a-b). Although the present study confirmed the important role of ropinirole (intraperitoneal and intrathecal administrations) in the pain process, other non-dopaminergic processes should not be excluded. Ropinirole is D3/D2 receptor agonist with very little affinity for D4 and no affinity for D1/D5, serotonin, histamine, acetylcholine, muscarinic, opioids, or adrenergic receptors (Wood, 2008). Ropinirole binds to D2 like receptors with avoiding ergot-like side effects. Ropinirole activates D2 receptors in the central and peripheral nervous systems. The efficiency of ropinirole was better than that of bromocriptine after 3 years of treatment. In different animal models, ropinirole had an antiparkinsonian effect (Fukuzaki et al., 2000). The ropinirole antiparkinsonian effect depends on both D2R and D3R (Matsukawa et al., 2007). To sum up, Ropinirole -as dopamine agonist- is effective as a therapy for early and progressing PD symptoms. This includes pain, as some studies have shown that, in PD models, unilateral injury led to bilateral dorsal horn spinal cord neuron hyperexcitability and augmented D2R function bilaterally (Shill & Stacy, 2009; Tang et al., 2021).

The present study confirms that of Dieb and Hafidi, 2015, except that, here, the stimulus is acetone. Although, to date, there is no proof in the literature of direct projections from SNc/VTA to the spinal cord. There is, however, some evidence that SNc/VTA may influence brainstem descending inhibitory pathways (Beckstead et al., 1979; Comissiong et al., 1979; Loughlin and Fallon, 1984; Ikemoto, 2007; Halliday et al., 2012). For example, the stimulation of SNc inhibits nociceptive input by activating spinal cord neurons through dopaminergic descending pathways (Barnes et al., 1979; Burkey et al., 1999).

Together, these data indicate that dopamine probably regulates the pain process by decreasing excitation in the dorsal horn PKC γ cells. PKC γ cells represent a key cell for switching non-noxious stimuli to the nociceptive pathway (Dieb and Hafidi, 2015; Dieb et al., 2015; Dieb et al., 2016 a-b).

PKC γ is expressed only in the excitatory interneurons in the rat spinal cord (Todd, 2017) and these neurons contribute to the SDH sensitization. PKC γ protein expression upregulation was observed in different pain models (Zhou et al., 2012; Dieb et al., 2014; Dieb et

al., 2016). PKC γ mutant mice displayed normal responses to acute painful stimuli but did not display the exaggerated response to noxious stimuli usually seen after partial sciatic nerve section (Malmberg et al., 1997). Glutamate release and the activation of NMDA receptor-induced both upregulation of PKC γ protein and its translocation from the plasma membrane to the cytosol. PKC γ positive cells project endings to pERK1/2 positive cells within the medullary dorsal horn (Dieb et al., 2015). The inhibition of PKC γ decreased the expression of pERK1/2 and alleviated the allodynia (Dieb et al., 2015). Moreover, several studies have shown that repetitive morphine exposure increased the level of PKC γ protein in the SDH (Mao et al., 1995). PKC γ mutant mice failed to exhibit opioid tolerance (Zeitz et al., 2001).

Another way of increasing excitation at the level of SDH is by decreasing the inhibition or, by disinhibition. Such mechanisms have been described in medullary and spinal dorsal horns where a decrease in GABA transmission promoted pain (Castro-Lopes et al., 1993; Ibuki et al., 1997; Eaton et al., 1998; Dieb and Hafidi, 2015). In the present study, both immunohistochemistry and western blots demonstrated an increase in GAD67. There is a converse correlation between the synthesis of GABA and the expression of GAD67 (Rimval and Martin, 1992). GAD67 activity is regulated by GABA feedback, and this activity declined when GABA levels were elevated. Therefore, the high expression of GAD67 in the dorsal horn of 6-OHDA-lesioned rats may have reflected a decrease in GABA levels. This decrease, in turn, increased the excitation of PKC γ cells as reported previously (Dieb and Hafidi, 2015). The 6-OHDA-lesioned rats presented both mechanical allodynia and hyperalgesia, in addition to thermal hyperalgesia.

GAD67 expression is controlled by dopamine. For example, dopamine depletion or D2R antagonists produced an increase in GAD67 expression (Soghomonian and Chesselet, 1992; Périer et al., 2003; Winkler et al., 2003; Billings and Marshall, 2004). Moreover, levodopa treatment reversed GAD67 mRNA overexpression in 6-OHDA-lesioned rats (Bacci et al., 2002; Périer et al., 2003). Although there is no previous report in the literature on this at the spinal cord level, to the best of our knowledge, the administration of ropinirole decreased GAD67 expression in the spinal dorsal horn, as demonstrated by immunohistochemistry and western blot. Dopamine depletion (SNc/VTA) could regulate GAD67 expression via brainstem descending inhibitory pain pathways or, directly, via dopaminergic hypothalamic nuclei (A11). SNc/VTA project to A11 nucleus. The latter is known to project directly to the spinal cord (Björklund and Skagerberg, 1979; Hokfelt et al., 1979; Skagerberg and Lindvall, 1985; Ozawa et al., 2017).

In the present study, 6-OHDA targeted both SNc and VTA, two nuclei that almost project to similar ascending (cortical and subcortical) or descending (brainstem) structures (Beckstead et al., 1979; Loughlin and Fallon 1984; Ikemoto, 2007; Halliday et al., 2012), which are part of the medial pain system. The neuronal activity in this system is regulated by nociceptive stimuli (Chudler and Dong, 1995; Cortelli et al., 2013) and by dopamine (Schultz and Romo, 1987; Mitsi and Zachariou, 2016). Therefore, the impact of the SNc/VTA lesion on pain is considered as a whole and not each nucleus separately. Both nuclei are affected by the 6-OHDA injection to the MFB. First, the primary target of these structures is the striatum (dorsal and ventral) which plays an important role in pain regulation. Striatal administration of D2R agonists had an anti-nociceptive effect (Lin et al., 1981; Cobacho et al., 2010) mediated by the rostral ventromedial medulla (RVM) (Ansah et al., 2007). Insular and cingulate cortices regulate pain (Chudler and Dong, 1995; Mitsi and Zachariou, 2016; Alles and Smith, 2018). However, a major difference between the SNc and the VTA is that the latter modulates the perception of the affective pain and the reward related pain (Chudler and Dong 1995). Acetone stimulation increased the expression of pERK1/2 in the insular and cingulate cortices, hence demonstrating their implication in the pain process in 6-OHDAlesioned rats. The administration of ropinirole significantly decreased the number of pERK1/2 positive cells in both structures, demonstrating the role of dopamine regulation in this expression. A decreased cold pain threshold has been shown in PD patients, and Levodopa administration normalized it (Brefel-Courbon et al., 2005; 2013). Similarly, over-activation in the insular and cingulate cortices was observed in pain-free PD subjects who were off levodopa at the time in comparison to healthy subjects (Brefel-Courbon et al., 2005).

In conclusion, the present study demonstrated cold and mechanical allodynia and mechanical hyperalgesia in 6-OHDA-lesioned rats. Acetone stimulus activated neurons within superficial spinal dorsal laminae, cingulate and insular cortices.

Acknowledgments: The Missions Sector of the Ministry of Higher Education and Scientific Research of the Arab Republic of Egypt; Ain Shams University, Egypt and Clermont Auvergne University, France funded this study and all authors declare that there is no conflict of interest.

References:

Adams JP, Anderson AE, Varga AW, Dineley KT, Cook RG, Pfaffinger PJ, Sweatt JD (2000) The A-type potassium channel Kv4.2 is a substrate for the mitogen-activated protein kinase ERK. J Neurochem 75:2277-2287.

Alles SRA, Smith PA (2018) Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev 70(2):315-347.

Altier N, Stewart J (1999) The role of dopamine in the nucleus accumbens in analgesia. Life Sci 65:2269–2287.

Ansah OB, Leite-Almeida H, Wei H, Pertovaara A (2007) Striatal dopamine D2 receptors attenuate neuropathic hypersensitivity in the rat. Exp Neurol 205:536–546.

Bacci JJ, Salin P, Kerkerian-Le Goff L (2002) Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model. Synapse 46(4):224-234.

Balayssac D, Ling B, Ferrier J, Pereira B, Eschalier A, Authier N (2014) Assessment of thermal sensitivity in rats using the thermal place preference test: description and application in the study of oxaliplatin-induced acute thermal hypersensitivity and inflammatory pain models. Behav Pharmacol 25(2):99-111.

Barcelo´ AC, Filippini B, Pazo JH (2010) Study of the neural basis of striatal modulation of the jaw-opening reflex. J Neural Transm 117:171–181.

Barnes CD, Fung SJ, Adams WL (1979) Inhibitory effects of substantia nigra on impulse transmission from nociceptors. Pain 6:207–215.

Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E, Cannas A, Ceravolo G et al. (2009) The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24(11):1641-1649.

Beckstead RM, Domesick VB, Nauta WJH (1979) Efferent connections of the substantia nigra and ventral tegmental area in the rat. Brain Research 175(2): 191-217.

Billings LM, Marshall JF (2004) Glutamic acid decarboxylase 67 mRNA regulation in two globus pallidus neuron populations by dopamine and the subthalamic nucleus. J Neurosci 24(12):3094-3103.

Björklund A, Skagerberg G (1979) Evidence for a major spinal cord projection from the diencephalic A 11 dopamine cell group in the rat using transmitter-specific fluorescent retrograde tracing. Brain Research 177(1):170-175.

Blanchet PJ, Brefel-Courbon C (2018) Chronic pain and pain processing in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 87(Pt B):200-206.

Borsook D (2012) Neurological diseases and pain. Brain 135:320–344.

Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O (2005) Effect of levodopa on pain threshold in Parkinson's disease: a clinical and positron emission tomography study. Mov Disord 20(12):1557-1563.

Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O (2013) Nociceptive brain activation in patients with neuropathic pain related to Parkinson's disease. Parkinsonism Relat Disord 19(5):548-552.

Buhidma Y, Rukavina K, Chaudhuri KR, Duty S (2020) Potential of animal models for advancing the understanding and treatment of pain in Parkinson's disease. npj Parkinsons Dis 6:1.

Buhmann C, Kassubek J and Jost WH (2020) Management of Pain in Parkinson's Disease. Journal of Parkinson's disease 10(s1): S37–S48.

Burkey A, Carstens E, Jasmin L (1999) Dopamine reuptake inhibition in the rostral agranular insular cortex produces antinociception. J Neurosci 19:4169–4179.

Campos ACP, Berzuino MB, Hernandes MS, Fonoff ET, Pagano RL (2019) Monoaminergic regulation of nociceptive circuitry in a Parkinson's disease rat model. Experimental Neurology 318: 12-21.

Castro-Lopes JM, Tavares I, Coimbra A (1993) GABA decreases in the spinal cord horn after peripheral neurectomy. Brain Res 620:287–291.

Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53(1):55-63.

Charles KA, Naudet F, Bouali-Benazzouz R, Landry M, De Deurwaerdère P, Fossat P, Benazzouz A (2018) Alteration of nociceptive integration in the spinal cord of a rat model of Parkinson's disease. Mov Disord 33(6):1010-1015.

Choi Y, Yoon YW, Na HS, Kim SH, Chung JM (1994) Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59:369-376.

Chudler EH, Dong WK (1995) The role of the basal ganglia in nociception and pain. Pain 60:3–38.

Chudler EH, Lu Y (2008) Nociceptive behavioral responses to chemical, thermal and mechanical stimulation after unilateral, intrastriatal administration of 6-hydroxydopamine. Brain Res 1213:41–47.

Cobacho N, De la Calle JL, Gonzalez-Escalada JR, Paíno CL (2010) Levodopa analgesia in experimental neuropathic pain. Brain Res Bull 83:304–309.

Commissiong JW, Gentleman S, Neff NH (1979) Spinal cord dopaminergic neurons: evidence for an uncrossed nigrospinal pathway. Neuropharmacology 18(6):565-568.

Cortelli P, Giannini G, Favoni V, Cevoli S, Pierangeli G (2013) Nociception and autonomic nervous system. Neurol Sci 34:41–46.

Cruz CD, Cruz F (2007) The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Current Neuropharmacology 5(4): 244–252.

Dieb W, Ouachikh O, Durif F, Hafidi A (2014) Lesion of the dopaminergic nigrostriatal pathway induces trigeminal dynamic mechanical allodynia. Brain Behav 4(3):368–380.

Dieb W, Alvarez P, Hafidi A (2015) PKC gamma-positive neurons gate light tactile inputs to pain pathway through pERK1/2 neuronal network in trigeminal neuropathic pain model. Journal of Oral & facial pain and headache 29:70-82.

Dieb W, Hafidi A (2015) Mechanism of GABA-involvement in posttraumatic trigeminal neuropathic pain: Activation of neuronal circuitry composed by PKC γ interneurons, and pERK1/2 expressing neurons. Eur J Pain 19:85–96.

Dieb W, Ouachikh O, Alves S, Boucher Y, Durif F, Hafidi A (2016) Nigrostriatal dopaminergic depletion increases static orofacial allodynia. J Headache Pain 17:11.

Dieb W, Ouachikh O, Durif F, Hafidi A (2016) Nigrostriatal dopaminergic depletion produces orofacial static mechanical allodynia. Eur J Pain 20(2):196-205.

Domenici RA, Campos ACP, Maciel ST, Berzuino MB, Hernandes MS, Fonoff ET, Pagano RL (2019) Parkinson's disease and pain: Modulation of nociceptive circuitry in a rat model of nigrostriatal lesion. Exp Neurol 315:72-81.

Dubin AE, Patapoutian A (2010) Nociceptors: the sensors of the pain pathway. The Journal of clinical investigation 120(11): 3760–3772.

Eaton MJ, Plunkett JA, Karmally S, Martinez MA, Montanez K (1998) Changes in GAD- and GABA-immunoreactivity in the spinal dorsal horn after peripheral nerve injury and promotion of recovery by lumbar transplant of immortalized serotonergic precursors. J Chem Neuroanat 16:57–72.

English JD, Sweatt JD (1996) Activation of p42 mitogen-activated protein kinase in hippocampal long term potentiation. J Biol Chem 271:24329-24332.

English JD, Sweatt JD (1997) A requirement for the mitogen-activated protein kinase cascade in hippocampal long term potentiation. J Biol Chem 272:19103-19106.

Ferro MM, Angelucci ME, Anselmo-Franci JA, Canteras NS, Da Cunha C (2007) Neuroprotective effect of ketamine/xylazine on two rat models of Parkinson's disease. Braz J Med Biol Res 40(1):89-96. Fil A, Cano-de-la-Cuerdab R, Muñoz-Hellínb E, Velac L, Ramiro-Gonzálezd M, Fernándezde-las-Peñasb C (2013) Pain in Parkinson disease: A review of the literature Parkinsonism Relat Disord 19(3):285-94.

Fukui T, Dai Y, Iwata K, Kamo H, Yamanaka H, Obata K, Kobayashi K, Wang S, Cui X, Yoshiya S, Noguchi K (2007) Frequency-dependent ERK phosphorylation in spinal neurons by electric stimulation of the sciatic nerve and the role in the electrophysiological activity. Mol Pain 16:3-18.

Fukuzaki K, Kamenosono T, Nagata R (2000) Effects of ropinirole on various parkinsonian models in mice, rats, and cynomolgus monkeys. Pharmacol Biochem Behav 65(3):503-508.

Guan Y, Borzan J, Meyer RA, Raja, SN (2006) Windup in dorsal horn neurons is modulated by endogenous spinal mu-opioid mechanisms. The Journal of neuroscience: the official journal of the Society for Neuroscience 26(16):4298–4307.

Halliday G, Reyes S, Double K (2012) Substantia Nigra, Ventral Tegmental Area, and Retrorubral Fields. In: The human nervous system, ed. 3 (Mai JK, Paxinos G), ch 13, pp 439-455. Academic Press.

Harris HN, Peng YB (2020) Evidence and explanation for the involvement of the nucleus accumbens in pain processing. Neural Regen Res 15(4):597-605.

Hokfelt T, Phillipson O, Goldstein M (1979) Evidence for a dopaminergic pathway in the rat descending from the A11 cell group to the spinal cord. Acta Physiol Scand 107:393–395.

Hu HJ, Carrasquillo Y, Karim F, Jung WE, Nerbonne JM, Schwarz TL, Gereau RW 4th (2006) The kv4.2 potassium channel subunit is required for pain plasticity. Neuron 50:89-100.

Hu HJ, Gereau RW (2003) ERK integrates PKA and PKC signaling in superficial dorsal horn neurons II. Modulation of neuronal excitability. J Neurophysiol 90:1680–1688.

Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J (1997) Loss of GABA-immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion of recovery by adrenal medullary grafts. Neuroscience 76:845–858.

Ikemoto S (2007) Dopamine reward circuitry: two projection systems from the ventral midbrain to the nucleus accumbens-olfactory tubercle complex. Brain research reviews 56(1):27–78.

Jankovic J, Tan EK (2020) Parkinson's disease: etiopathogenesis and treatment. Journal of Neurology, Neurosurgery & Psychiatry 91:795-808.

Jensen TS, Finnerup NB (2014) Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms. The Lancet Neurology 13:924–935.

Ji RR, Baba H, Brenner GJ, Woolf CJ (1999) Nociceptive-specific activation of ERK in spinal neurons contributes to pain hypersensitivity. Nat Neurosci 2:1114–1119.

Jones MW, French PJ, Bliss TV, Rosenblum K (1999) Molecular mechanisms of long-term potentiation in the insular cortex. J Neurosci 19:RC36 (1-8).

Lin MT, Wu JJ, Chandra A, Tsay BL (1981) Activation of striatal dopamine receptors induces pain inhibition in rats. J Neural Trans 51:213–222.

Liu MG, Matsuura S, Shinoda M, Honda K, Suzuki I, Shibuta K, Tamagawa T, Katagiri A, Kiyomoto M, Ohara K, Furukawa A, Urata K, Iwata K (2012) Metabotropic glutamate receptor 5 contributes to inflammatory tongue pain via extracellular signal-regulated kinase signaling in the trigeminal spinal subnucleus caudalis and upper cervical spinal cord. Journal of neuroinflammation 9:258.

Loughlin SE, Fallon JH (1984) Substantia nigra and ventral tegmental area projections to cortex: topography and collateralization. Neuroscience 11(2):425-435.

Magnusson JE, Fisher K (2000) The involvement of dopamine in nociception: The role of D(1) and D(2) receptors in the dorsolateral striatum. Brain Res 855(2):260-266.

Malmberg AB, Chen C, Tonegawa S, Basbaum AI (1997) Preserved acute pain and reduced neuropathic pain in mice lacking PKCgamma. Science 278:279–283.

Mao J, Price DD, Phillips LL, Lu J, Mayer DJ (1995) Increases in protein kinase C gamma immunoreactivity in the spinal cord of rats associated with tolerance to the analgesic effects of morphine. Brain Res 677:257–267.

Marques A, Chassin O, Morand D, Pereira B, Debilly B, Derost P, Ulla M, Lemaire JJ, Durif F (2013) Central pain modulation after subthalamic nucleus stimulation: A crossover randomized trial. Neurology 81:633–640.

Martin SJ, Grimwood PD, Morris RG (2000) Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 23:649-711.

Matsukawa N, Maki M, Yasuhara T, Hara K, Yu G, Xu L, Kim KM, Morgan JC, Sethi KD, Borlongan, CV (2007) Overexpression of D2/D3 receptors increases the efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats. Brain Research 1160:113–123.

Mavrikaki M, Schintu N, Nomikos GG, Panagis G, Svenningsson P (2014) Ropinirole regulates emotionality and neuronal activity markers in the limbic forebrain. International Journal of Neuropsychopharmacology 17(12):1981–1993.

Mestre C, Pelissier T, Fialip J, Wilcox G, Eschalier A (1994) A method to perform direct transcutaneous intrathecal injection in rats. J Pharmacol Toxicol Methods 4:197–200.

Mitsi V, Zachariou V (2016) Modulation of pain, nociception, and analgesia by the brain reward center. Neuroscience 338:81–92.

Mylius V, Ciampi de Andrade D, Cury RG, Teepker M, Ehrt U, Eggert KM, Beer S, Kesselring J, Stamelou M, Oertel WH, Möller JC, Lefaucheur JP (2015) Pain in Parkinson's

Disease: Current Concepts and a New Diagnostic Algorithm. Mov Disord Clin Pract 2(4):357-364.

Ohara PT, Granato A, Moallem TM, Wang BR, Tillet Y, Jasmin L (2003) Dopaminergic input to GABAergic neurons in the rostral agranular insular cortex of the rat. J Neurocytol 32(2):131-141.

Ohara PT, Vit JP, Jasmin L (2005) Cortical modulation of pain. Cell Mol Life Sci 62(1):44-52.

Ouachikh O, Dieb W, Durif F, Hafidi A (2013) Differential behavioral reinforcement effects of dopamine receptor agonists in the rat with bilateral lesion of the posterior ventral tegmental area. Behav Brain Res 1(252):24-31.

Ouachikh O, Dieb W, Durif F, Hafidi A (2014) Anterior ventral tegmental area dopaminergic neurons are not involved in the motivational effects of bromocriptine, pramipexole, and cocaine in drug-free rats. Behav Brain Res 1(262):1-7.

Ozawa H, Yamaguchi T, Hamaguchi S, Yamaguchi S, Ueda S (2017) Three Types of A11 Neurons Project to the Rat Spinal Cord. Neurochem Res 42:2142–2153.

O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 23(1):101-106.

Paillé V, Henry V, Lescaudron L, Brachet P, Damier P (2007) Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Mov Disord 22:533–539.

Pasquier DA, Kemper TL, Forbes WB, Morgane PJ (1977) Dorsal raphe, substantia nigra and locus coeruleus: interconnections with each other and the neostriatum. Brain Res Bull 2(5):323-339.

Périer C, Marin C, Jimenez A, Bonastre, M, Tolosa E, Hirsch EC (2003) Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats: STN or EP lesion on levodopa-induced changes. Journal of Neurochemistry 86(6):1328–1337.

Polgár E, Campbell AD, MacIntyre LM, Watanabe M, Todd AJ (2007) Phosphorylation of ERK in neurokinin 1 receptor-expressing neurons in laminae III and IV of the rat spinal dorsal horn following noxious stimulation. Molecular pain 3:4.

Ramji JV, Keogh JP, Blake TJ, Broom C, Chenery RJ, Citerone DR, Lewis VA, Taylor AC, Yeulet SE (1999) Disposition of ropinirole in animals and man. Xenobiotica 29(3):311-325.

Randall LO, Selitto JJ (1957) A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111(4):409-419.

Rimvall K, Martin DL (1992) Increased intracellular gamma-aminobutyric acid selectively lowers the level of the larger of two glutamate decarboxylase proteins in cultured GABAergic neurons from rat cerebral cortex. J Neurochem 58(1):158-166.

Saadé NE, Atweh SF, Bahuth NB, Jabbur SJ (1997) Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res 751:1–12.

Sandkühler J (2009) Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 89:707–758.

Schafe GE, Atkins CM, Swank MW, Bauer EP, Sweatt JD, LeDoux JE (2000) Activation of ERK/MAP kinase in the amygdala is required for memory consolidation of pavlovian fear conditioning. J Neurosci 20:8177-8187.

Shill HA, Stacy M (2009) Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 5:33-36.

Schultz W, Romo R (1987) Responses of nigrostriatal dopamine neurons to high-intensity somatosensory stimulation in the anesthetized monkey. J Neurophysiol 57:201–217.

Simone DA, Kajander KC (1996) Excitation of rat cutaneous nociceptors by noxious cold. Neurosci Lett 213(1):53-56.

Skagerberg G, Lindvall O (1985) Organization of diencephalic dopamine neurons projecting to the spinal cord in the rat. Brain Res 342: 340–351.

Skogar O, Lokk J (2016) Pain management in patients with Parkinson's disease: challenges and solutions. Journal of multidisciplinary healthcare 9:469–479.

Sneddon LU (2018) Comparative Physiology of Nociception and Pain. Physiology (Bethesda) 33(1):63-73.

Soghomonian JJ, Chesselet MF (1992) Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat. Synapse 11(2):124-133.

Stamey W, Davidson A, Jankovic J (2008) Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol 14:253–254.

Takahashi Y, Nakajima Y, Sakamoto T (1994) Dermatome mapping in the rat hindlimb by electrical stimulation of the spinal nerves. Neurosci Lett 168(1-2):85-88.

Takeda R, Ikeda T, Tsuda F, Abe H, Hashiguchi H, Ishida Y, Nishimori T (2005) Unilateral lesions of mesostriatal dopaminergic pathway alters the withdrawal response of the rat hind paw to mechanical stimulation. Neurosci Res 52:31–36.

Tang Dl, Luan Yw, Zhou Cy, Xiao C (2021) D2 receptor activation relieves pain hypersensitivity by inhibiting superficial dorsal horn neurons in parkinsonian mice. Acta Pharmacol Sin 42:189–198.

Taylor AM, Murphy NP, Evans CJ, Cahill CM (2014) Correlation between ventral striatal catecholamine content and nociceptive thresholds in neuropathic mice. J Pain 15(8):878-885.

Todd AJ (2017). Identifying functional populations among the interneurons in laminae I-III of the spinal dorsal horn. Molecular pain 13:1744806917693003.

Tremblay M, Silveira MM, Kaur S, Hosking JG, Adams WK, Baunez C and Winstanley CA (2017) Chronic $D_{2/3}$ agonist ropinirole treatment increases preference for uncertainty in rats regardless of baseline choice patterns. Eur J Neurosci 45: 159-166.

Tseng MT, Lin CH (2017) Pain in early-stage Parkinson's disease: Implications from clinical features to pathophysiology mechanisms. Journal of the Formosan Medical Association 116(8):571-581.

Viana F (2018) Nociceptors: thermal allodynia and thermal pain. Handb Clin Neurol 156:103-119.

Von Krosigk M, Smith AD (1991) Descending Projections from the Substantia Nigra and Retrorubral Field to the Medullary and Pontomedullary Reticular Formation. Eur J Neurosci 3(3):260-273.

Wawrzczak-Bargieła A, Ziółkowska B, Piotrowska A, Starnowska-Sokol J, Rojewska E, Mika J, Przewlocka B, Przewlocki R (2020) Neuropathic Pain Dysregulates Gene Expression of the Forebrain Opioid and Dopamine Systems. Neurotox Res 37:800–814.

Wei F, Vadakkan KI, Toyoda H, Wu LJ, Zhao MG, Xu H, Shum FW, Jia YH, Zhuo M (2006) Calcium calmodulin-stimulated adenylyl cyclases contribute to activation of extracellular signal-regulated kinase in spinal dorsal horn neurons in adult rats and mice. J Neurosci 26:851–861.

Winkler C, Bentlage C, Cenci MA, Nikkhah G, Bjorklund A (2003) Regulation of neuropeptide mRNA expression in the basal ganglia by intrastriatal and intranigral transplants in the rat Parkin-son model. Neuroscience 118:1063 – 1077.

Wood PB (2006) Mesolimbic dopaminergic mechanisms and pain control. Pain 120:230–234.

Wood PB (2008) Role of central dopamine in pain and analgesia. Expert Rev Neurother 8(5):781-797.

Young Blood MR, Ferro MM, Munhoz RP, Teive HA, Camargo CH (2016) Classification and Characteristics of Pain Associated with Parkinson's Disease. Parkinson's disease 2016:6067132.

Zeitz KP, Malmberg AB, Gilbert H, Basbaum AI (2001) Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain 94: 245–253.

Zenken-Toktas Y, Authier N, Denizot H, Chassain C, Hafidi A, Llorca, PM, Durif F (2013) Motivational properties of D2 and D3 dopamine receptors agonists and cocaine, but not with D1 dopamine receptors agonist and L-dopa, in bilateral 6-OHDA lesioned rat. Neuropharmacology 70:74–82.

Zhang Y, Larcher KM, Misic B, Dagher A (2017) Anatomical and functional organization of the human substantia nigra and its connections. Elife 6:e26653.

Zou W, Zhan X, Li M, Song Z, Liu C, Peng F, Guo Q (2012) Identification of differentially expressed proteins in the spinal cord of neuropathic pain models with PKCgamma silence by proteomic analysis. Brain Res 1440:34-46.

Figure's legend

Figure 1: Thermal place preference behavioral test. The graph represents time spent on thermal test plates of the sham and 6-OHDA-lesioned groups. There were significant differences; Student's t-test, between the groups for temperatures 10 °C ($t_{10} = 4.02$, p = 0.002, **P ≤ 0.01), 15 °C ($t_{10} = 8.31$, p = 0.00001, ***P ≤ 0.001) and a non-significant difference for 35 °C ($t_{10} = 0.66$, p = 0.53, p > 0.05). While Mann- Whitney U test was used for 25 °C ($U_{6,6} = 10$, p = 0.22, p > 0.05) and 50 °C ($U_{6,6} = 4$, p = 0.03, *P ≤ 0.05). Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 6) and 6-OHDA-lesioned groups (n = 6).

Figure 2: Acetone cold allodynia behavioral test (Intraperitoneal administration of Ropinirole for 6-OHDA +D2R agonist group). Graph (A) represents the number of flinches for the three groups; Kruskal-Wallis H test (H₂ =17.23, p = 0.0002, ***P \leq 0.001): 6-OHDA-lesioned rats had more significant numbers than the sham ones (Dunn's multiple comparisons test, p =0.001, ***P \leq 0.001) also, the 6-OHDA +D2R agonist group had an increase in significance over the sham group (Dunn's multiple comparisons test, p = 0.01, ** $P \le 0.01$). Graph (B) represents the latency time of the three groups; Kruskal-Wallis H test ($H_2 = 15.13$, p = 0.0004, *** $P \le 0.001$), the 6-OHDA-lesioned rats had a more significant increase in latency time than both the sham and 6-OHDA +D2R agonist groups (Dunn's multiple comparisons tests, p =0.006, p = 0.04, respectively, $**P \le 0.01$, $*P \le 0.05$ respectively). Graph (C) represents the reaction time of the three groups; Kruskal-Wallis H test (H₂ = 28.58, p < 0.0001, ***P \leq 0.001): the 6-OHDA-lesioned group had a more significant increase in reaction time than both the sham and 6-OHDA +D2R agonist groups (Dunn's multiple comparisons test, p <0.0001, *** $P \le 0.001$). Data are represented as box-and-whiskers plots, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 11), 6-OHDA-lesioned (n = 23), and 6-OHDA+D2R agonist groups (n = 9).

Figure 3: Graph (A) represents mechanical hyperalgesia (Randall-test) at two and four weeks after surgery; Two-way ANOVA test with significant interaction, row and column factors (F₂, $_{30} = 479.6$, F₂, $_{30} = 695.4$, F₁, $_{30} = 197$ respectively, p < 0.0001, ***P ≤ 0.001): followed by (Sidak's multiple comparisons test, p < 0.0001, ***P ≤ 0.001). Data are represented as a line plot of the median ± interquartile range of sham (n = 6) and 6-OHDA-lesioned rats (n = 6). Graph (B) shows similar results using the non-noxious 10 g von Frey filament test at two and four weeks after surgery; Friedman's test ($\chi 2_2 = 16.84$, p < 0.001, ***P ≤ 0.001) followed by (Wilcoxon Signed-Rank Test, p < 0.0001, ***P ≤ 0.001). Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 6) and 6-OHDA-lesioned groups (n = 6).

Figure 4: pERK1/2 protein expression. The Figure shows pERK expression in the SDH of the sham (A), 6-OHDA-lesioned (B), and 6-OHDA +D2R agonist groups (C). Graph (D) represents pERK1/2 positive cells within the SDH superficial laminae; Kruskal-Wallis H test (H₂ =55.64, p < 0.0001, ***P \leq 0.001): 6-OHDA-lesioned rats had a more significant number than both the sham and 6-OHDA +D2R agonist groups (Dunn's multiple comparisons test, p < 0.0001, ***P \leq 0.001) also, the 6-OHDA +D2R agonist group had an increase in significance over the sham (Dunn's multiple comparisons test, p < 0.0001, *** $P \le 0.001$). Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 5), 6-OHDA-lesioned (n = 6), and D2R agonist groups (n = 6). The Scale bar represents 50 μ m. Figure (E) shows western blot bands of pERK1/2 for the three groups. Graph (F) represents western blot band intensities for the three groups; one-way ANOVA ($F_{2,6} = 10.29$, p = 0.012, *P \leq 0.05): The 6-OHDA-lesioned rats had a more significant increase in expression than both the sham and 6-OHDA +D2R agonist groups (Tukey's multiple comparisons test, p =0.02, p = 0.02 respectively, *P \leq 0.05). Data are represented as a barplot of the median ± interquartile range of the sham (n = 3), 6-OHDA-lesioned (n = 3) and 6-OHDA +D2R agonist groups (n = 3), GAPDH was used as the loading control.

Figure 5: PKC γ protein expression. The Figure shows PKC γ expression in the SDH of the sham (A), 6-OHDA-lesioned (B) and 6-OHDA +D2R agonist groups (C). PKC γ positive cells were observed within the SDH mostly in cells of lamina III and scattered cells within lamina III. Figure (B) has more intense fluorescent labeling than both Figures (A) and (C). The Scale bar represents 50 µm. Graph (D) represents PKC γ cell number count; Kruskal-Wallis H test

(H₂ =29.42, p < 0.0001, ***P \leq 0.001): the 6-OHDA-lesioned rats had a higher significant number than both the sham and 6-OHDA +D2R agonist groups (Dunn's multiple comparisons test, p= 0.0001, p <0.0001 respectively, ***P \leq 0.001). Data are represented as a box-andwhiskers plot, where the box depicts the median and the 25th and 75th quartiles, and the whiskers show the 5th and 95th percentile of the sham (n =6), 6-OHDA-lesioned (n = 7), and D2R agonist group (n = 6). Figure (E) shows the western blot bands of PKC γ for the three groups. Graph (F) represents western blot band intensities for the three groups, one-way ANOVA (F_{2, 9} = 1.11, p = 0.37, *p* > 0.05): the 6-OHDA-lesioned group had a less significant increase in expression than both the sham and 6-OHDA +D2R agonist groups (Tukey's multiple comparisons tests, p = 0.35, p = 0.65, respectively, *p* > 0.05). Data are represented as a barplot of the median \pm interquartile range of the sham (n = 4), 6-OHDA-lesioned (n = 4) and 6-OHDA +D2R agonist groups (n = 4), GAPDH was used as the loading control.

Figure 6: GAD67 protein expression. The Figure shows GAD67 expression in the SDH of the sham (A), 6-OHDA-lesioned (B), and 6-OHDA +D2R agonist groups (C). Figure (B) has more intense fluorescent labeling than both figures (A) and (C). The Scale bar represents 50 μ m. Figure (D) shows the western blot bands of GAD67 for the three groups. Graph (E) represents western blot band intensities for the three groups; Kruskal-Wallis test (H₂ =15.79, p < 0.0001, ***P ≤ 0.001): The 6-OHDA-lesioned rats had a more significant increase in expression than both the sham and 6-OHDA +D2R agonist groups (Dunn's multiple comparisons test, p = 0.03, p = 0.0004, respectively, *P ≤ 0.05, ***P ≤ 0.001). Data are represented as a barplot of the median ± interquartile range of the sham (n = 4), 6-OHDA-lesioned (n = 8) and 6-OHDA +D2R agonist groups (n = 8), GAPDH was used as the loading control.

Figure 7: pERK1/2 protein expression. The Figure shows pERK expression in the insular cortex of the sham (A), 6-OHDA-lesioned (B), and 6-OHDA +D2R agonist groups (C). Graph (D) represents pERK1/2 positive cells within the insular cortex; Kruskal-Wallis test $(H_2 = 25.71, p < 0.0001, ***P \le 0.001)$: the 6-OHDA-lesioned animals had more significant numbers than both the sham and 6-OHDA +D2R agonist groups (Tukey's multiple comparisons test, p < 0.0001, ***P ≤ 0.001). Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 6), 6-OHDA-lesioned (n = 6), and 6-OHDA +D2R agonist groups (n = 7). The Scale bar represents 50 µm. Figure (E) shows western blot bands of pERK1/2 for the three groups. Graph (F) represents western blot band intensities for the

three groups; one-way ANOVA ($F_{2, 6} = 6.60$, p= 0.031, $*P \le 0.05$): The 6-OHDA-lesioned group had a more significant increase in expression than both the sham and 6-OHDA +D2R agonist groups (Tukey's multiple comparisons test, p = 0.044, p = 0.046 respectively, $*P \le 0.05$). Data are represented as a barplot of the median \pm interquartile range of the sham (n = 3), 6-OHDA-lesioned (n = 3) and 6-OHDA +D2R agonist groups (n = 3), GAPDH was used as the loading control.

Figure 8: pERK1/2 protein expression. The Figure shows pERK expression in the cingulate cortex of the sham (A), 6-OHDA-lesioned (B), and 6-OHDA +D2R agonist groups (C). Graph (D) represents pERK1/2 positive cells within the cingulate cortex; one-way ANOVA ($F_{2, 47} = 14.36$, p < 0.0001, ***P \leq 0.001): the 6-OHDA-lesioned rats had more significant numbers than both the sham and 6-OHDA +D2R agonist groups (Tukey's multiple comparisons test, p < 0.0001, ***P \leq 0.001). Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 6), 6-OHDA lesioned (n = 6), and 6-OHDA +D2R agonist groups (n = 7). The Scale bar represents 100 µm. Figure (E) shows western blot bands of pERK1/2 for the three groups. Graph (F) represents western blot band intensities for the three groups; one-way ANOVA ($F_{2, 6} = 5.34$, p = 0.047, *P \leq 0.05): the 6-OHDA-lesioned group had a more significant increase in expression than the sham group (Tukey's multiple comparisons test, p = 0.048, *P \leq 0.05). Data are represented as a barplot of the median \pm interquartile range of the sham (n = 4), 6-OHDA-lesioned (n=4) and 6-OHDA + D2R agonist groups (n = 4), GAPDH was used as the loading control.

Figure 9: A significant allodynic behavior was observed in the hind paws in the 6-OHDAlesioned rats. The allodynic behavior decreased almost immediately with the intrathecal administration of ropinirole in the 6-OHDA-lesioned rats; two-way ANOVA test with significant interaction, row and column factors (F_{6, 70} = 14.08, F_{6, 70} = 17.80, F_{1, 70} = 147.9, respectively, p < 0.0001, ***P \leq 0.001): followed by (Sidak's multiple comparisons test: p < 0.0001, ***P \leq 0.001). This effect lasted for almost 25 minutes. Data are represented as a line plot of the median ± interquartile range of the sham (n = 6) and 6-OHDA- lesioned rats (n = 6).

Figure 10: TH immunostaining in the sham (A) and 6-OHDA-lesioned animals (B) shows a profound decrease in the intensity of staining, in both the SNc and the VTA in the 6-OHDA-lesioned rats when compared with the sham ones. The Cell count of the TH positive cells in

both the SNc and the VTA together; Mann-Whitney test $(U_{27,15}=18, p < 0.0001, ***P \le 0.001)$ (C) or in the VTA only; Mann-Whitney test $(U_{28,13}=45, p < 0.0001, ***P \le 0.001)$ (D) or in the SNc only; Mann-Whitney test $(U_{28,13}=2, p < 0.0001, ***P \le 0.001)$ (E) revealed a significant difference between the 6-OHDA-lesioned and the sham groups. Cell death percentage in both the SNc and the VTA was 67.8 %, in VTA only, it was 56.7 % and in the SNc, it only was 89.9 % after 6-OHDA lesion. Data are represented as a box-and-whiskers plot, where the box depicts the median and the 25th and 75th quartiles and the whiskers show the 5th and 95th percentile of the sham (n = 5) and 6-OHDA-lesioned groups (n = 6). The Scale bar represents 200 µm. The graph (F) represents data from two animal groups: sham (n = 11) and 6-OHDA-lesioned (n = 18). A significant decrease in weight difference (Student's T-test) was observed in the 6-OHDA-lesioned group in comparison to the sham rats after surgery $(p = 0.027, * P \le 0.05)$.

Figure 11: Behavioral Experiments Time Course. 6-OHDA (6-hydroxydopamine) and VFT (von Frey test).











pERK12 GAPDH

toint 40.08-





















